P-cresyl sulfate is a valuable predictor of clinical outcomes in pre-ESRD patients

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Lin, Cheng Jui ^a   Pan, Chi Feng ^a   Chuang, Chih Kuang ^a,b,c   Sun, Fang Ju ^a   Wang, Duen Jen ^d   Chen, Han Hsiang ^a   Liu, Hsuan Liang ^a   Wu, Chih Jen ^a,e,f  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^c NATIONAL TAIPEI UNIVERSITY OF TECHNOLOGY   (Taiwan)

^d FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f MACKAY MEDICAL COLLEGE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

4 CRESYL SULFATE; ALBUMIN; CREATININE; HEMOGLOBIN; PARATHYROID HORMONE; SERUM ALBUMIN; UNCLASSIFIED DRUG; UREMIC TOXIN; 4 CRESOL SULFATE; 4-CRESOL SULFATE; BIOLOGICAL MARKER; CRESOL; SULFATE;

ADULT; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEMATOCRIT; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; AGED; BLOOD; CHRONIC KIDNEY FAILURE; KAPLAN MEIER METHOD; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RENAL REPLACEMENT THERAPY;

AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CRESOLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SULFURIC ACID ESTERS; TREATMENT OUTCOME;

EID: 84896808990     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/526932     Document Type: Article

References (27)

1. Keith D. S., Nichols G. A., Gullion C. M., Brown J. B., Smith D. H., Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Archives of Internal Medicine 2004 164 6 659 663 2-s2.0-1642413198 10.1001/archinte.164.6.659
2. Sarnak M. J., Levey A. S., Schoolwerth A. C., Coresh J., Culleton B., Hamm L. L., McCullough P. A., Kasiske B. L., Kelepouris E., Klag M. J., Parfrey P., Pfeffer M., Raij L., Spinosa D. J., Wilson P. W., Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003 42 5 1050 1065 2-s2.0-0242441465 10.1161/01.HYP.0000102971. 85504.7c
3. Go A. S., Chertow G. M., Fan D., Chronic kidney disease and the risks of death, cardiovascular events, andhospitalization. The New England Journal of Medicine 2004 351 13 1296 1305
4. Sarnak M. J., Coronado B. E., Greene T., Wang S.-R., Kusek J. W., Beck G. J., Levey A. S., Cardiovascular disease risk factors in chronic renal insufficiency. Clinical Nephrology 2002 57 5 327 335 2-s2.0-0035989794
5. Clarke R., Daly L., Robinson K., Naughten E., Cahalane S., Fowler B., Graham I., Hyperhomocysteinemia: an independent risk factor for vascular disease. The New England Journal of Medicine 1991 324 17 1149 1155 2-s2.0-0025756673
6. Culleton B. F., Wilson P. W., Cardiovascular disease: risk factors, secular trends, and therapeutic guidelines. Journal of the American Society of Nephrology 1998 9 12 5 15 2-s2.0-0032229832
7. Sarnak M. J., Levey A. S., Cardiovascular disease and chronic renal disease: a new paradigm. The American Journal of Kidney Diseases 2000 35 4 S117 S131 2-s2.0-0034079643
8. Longenecker J. C., Coresh J., Powe N. R., Levey A. S., Fink N. E., Martin A., Klag M. J., Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE study. Journal of the American Society of Nephrology 2002 13 7 1918 1927 2-s2.0-0036287767 10.1097/01.ASN.0000019641.41496.1E
9. Krieter D. H., Hackl A., Rodriguez A., Chenine L., Moragues H. L., Lemke H.-D., Wanner C., Canaud B., Protein-bound uraemic toxin removal in haemodialysis and post-dilution haemodiafiltration. Nephrology Dialysis Transplantation 2010 25 1 212 218 2-s2.0-72949119098 10.1093/ndt/gfp437
10. Meijers B. K., Van kerckhoven S., Verbeke K., Dehaen W., Vanrenterghem Y., Hoylaerts M. F., Evenepoel P., The Uremic Retention Solute p-Cresyl Sulfate and Markers of Endothelial Damage. The American Journal of Kidney Diseases 2009 54 5 891 901 2-s2.0-70350031206 10.1053/j.ajkd.2009.04.022
11. Dou L., Bertrand E., Cerini C., Faure V., Sampol J., Vanholder R., Berland Y., Brunet P., The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney International 2004 65 2 442 451 2-s2.0-1642480079 10.1111/j.1523-1755.2004.00399.x
12. Meijers B. K., Bammens B., de Moor B., Verbeke K., Vanrenterghem Y., Evenepoel P., Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney International 2008 73 10 1174 1180 2-s2.0-42949119698 10.1038/ki.2008.31
13. Lin C. J., Wu C. J., Pan C. F., Chen Y. C., Sun F. J., Chen H. H., Serum protein-bound uraemic toxins and clinical outcomes in haemodialysis patients. Nephrology Dialysis Transplantation 2010 25 11 3693 3700 2-s2.0-79952200542
14. Bammens B., Evenepoel P., Keuleers H., Verbeke K., Vanrenterghem Y., Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney International 2006 69 6 1081 1087 2-s2.0-33644872268 10.1038/sj.ki.5000115
15. Lin C. J., Pan C. F., Liu H. L., The role of protein-bound uremic toxins on peripheral artery disease and vascular access failure in patients on hemodialysis. Atherosclerosis 2012 225 1 173 179
16. Foley R. N., Parfrey P. S., Sarnak M. J., Epidemiology of cardiovascular disease in chronic renal disease. Journal of the American Society of Nephrology 1998 9 12 S16 S23 2-s2.0-0032229826
17. Halcox J. P. J., Schenke W. H., Zalos G., Mincemoyer R., Prasad A., Waclawiw M. A., Nour K. R. A., Quyyumi A. A., Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002 106 6 653 658 2-s2.0-0037031266 10.1161/01.CIR.0000025404.78001.D8
18. Masai N., Tatebe J., Yoshino G., Morita T., Indoxyl sulfate stimulates monocyte chemoattractant protein-1 expression in human umbilical vein endothelial cells by inducing oxidative stress through activation of the NADPH oxidase-nuclear factor- B pathway. Circulation Journal 2010 74 10 2216 2224 2-s2.0-77958044174 10.1253/circj.CJ-10-0117
19. Lin C. J., Chen H. H., Pan C. F., Chuang C. K., Wang T. J., Sun F. J., Wu C. J., p-cresylsulfate and indoxyl sulfate level at different stages of chronic kidney disease. Journal of Clinical Laboratory Analysis 2011 25 3 191 197 2-s2.0-79955883106 10.1002/jcla.20456
20. Schepers E., Meert N., Glorieux G., Goeman J., van der Eycken J., Vanholder R., P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrology Dialysis Transplantation 2007 22 2 592 596 2-s2.0-33846659447 10.1093/ndt/gfl584
21. Vanholder R., Argilés A., Baurmeister U., Brunet P., Clark W., Cohen G., de Deyn P. P., Deppisch R., Descamps-Latscha B., Henle T., Jörres A., Massy Z. A., Rodriguez M., Stegmayr B., Stenvinkel P., Wratten M. L., Uremic toxicity: present state of the art. International Journal of Artificial Organs 2001 24 10 695 725 2-s2.0-0035199052
22. Liabeuf S., Barreto D. V., Barreto F. C., Meert N., Glorieux G., Schepers E., Temmar M., Choukroun G., Vanholder R., Massy Z. A., Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrology Dialysis Transplantation 2010 25 4 1183 1191 2-s2.0-77950234472 10.1093/ndt/gfp592
23. Lin C. J., Pan C. F., Chuang C. K., Gastrointestinal-related uremic toxins in peritoneal dialysis: a pilot study with a 5-year follow-up. Archives of Medical Research 2013 44 7 535 541
24. Wang C. P., Lu L. F., Yu T. H., Hung W. C., Chiu C. A., Chung F. M., Yeh L. R., Chen H. J., Lee Y. J., Houng J. Y., Serum levels of total p-cresylsulphate are associated with angiographic coronary atherosclerosis severity in stable angina patients with early stage of renal failure. Atherosclerosis 2010 211 2 579 583 2-s2.0-77955263041 10.1016/j.atherosclerosis. 2010.03.036
25. Watanabe H., Miyamoto Y., Honda D., Tanaka H., Wu Q., Endo M., Noguchi T., Kadowaki D., Ishima Y., Kotani S., Nakajima M., Kataoka K., Kim-Mitsuyama S., Tanaka M., Fukagawa M., Otagiri M., Maruyama T., p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase. Kidney International 2013 83 4 582 592
26. Tumur Z., Niwa T., Indoxyl sulfate inhibits nitric oxide production and cell viability by inducing oxidative stress in vascular endothelial cells. The American Journal of Nephrology 2009 29 6 551 557 2-s2.0-58149146910 10.1159/000191468
27. Yu M., Kim Y. J., Kang D. H., Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clinical Journal of the American Society of Nephrology 2011 6 1 30 39 2-s2.0-79251528072 10.2215/CJN.05340610